Clinically relevant models for cancer therapy development
We are committed to providing academic PIs the most innovative pre-clinical models and services to delineate the mechanisms underlying disease and enable you to select efficacious drugs, including a range of immunotherapeutics to treat targeted tumor types alone or in combination.
In collaboration with 25 national medical centers, we have banked over 400 Patient-Derived Xenograft (PDX) models, many with detailed clinical information, such as including treatment history and extensive characterization, established in the highly immunodeficient NSG™ mice.
Our PDX Live™ collection includes 16 different PDX models - all of which are maintained live in mice for quicker delivery. These PDX Live™ tumors are now available at a special price. Other cryopreserved models are also available – contact us for details.
Our PDX program for academic PIs provides tumor models at a lower passage, more accurately reflecting clinical samples compared to other PDX resources. Other advantages include:
Early passage samples retain cancer heterogeneity.
Models are grown directly from clinical samples, not cell lines.
Clinician-directed program includes current patient demographics.
Cancer models reflect a spectrum of relevant mutations.
To take advantage of special pricing for academic PIs, contact your regional representative.
PDX-engrafted mice are a fast and cost-effective platform to simulate trials, evaluate multiple drugs alone or in combination, and produce predictive data.
Pilot Combination Study Using a PDX Live™ Colon Adenocarcinoma
Figure 1. Mice bearing passage 3 colon adenocarcinoma PDX tumor (TM00170) were treated with vehicle control: D5W (dark grey), 20mg/ kg 5-Fu (light blue), 10mg/kg Oxaliplatin (orange) and 5-Fu + Oxaliplatin (dark blue) once per week for 3 weeks. Vehicle and 5-Fu were administrated intravenously and Oxaliplatin was dosed intraperitoneally. The readout for compound efficacy–alone or in combination-was assessed by taking tumor caliper measurements and body weight twice weekly. Ten NSG™ mice were used per arm.
Pilot Combination Study Using a PDX Live™ Invasive Ductal Carcinoma
Figure 2. Mice bearing passage 4 TM00089 PDX tumor were treated with vehicle control (D5W), Cisplatin (2mg/kg), Cyclophosphamide (40mg/kg) and Doxorubicin (2mg/kg) intravenously, once per week for 3 weeks; Docetaxel (15mg/kg) was dosed once per week only for 2 weeks intravenously.
3A. 3B. 3C.
Figure 3. A) Patient tumor for PDX model TM00089 (aka, BR0620); PR marker (negative). B) P0 tumor #037 for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker. C) P1 tumor for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker (negative)
Pilot Combination Study Using a PDX Live™ Lung Adenocarcinoma
Figure 4. Mice bearing TM00199 PDX samples at passage 3 were used to create five treatment groups of twelve mice each: vehicle control (0.5 % carboxymethylcellulose); erlotinib (50 mg/kg); afatinib (20 mg/kg); cetuximab (10 mg/kg); and afatinib plus cetuximab (20 mg/kg and 10 mg/kg, respectively). Vehicle, erlotinib, and afatinib were IP dosed daily for 21 days. Cetuximab was dosed intravenously three times weekly, for three weeks. Mice were monitored for tumor volume.
Figure 5. A) P1 tumor #940_001 for PDX model TM00199 (aka, LG0703F). B) P1 tumor #940_006 for PDX model TM00199 (aka, LG0703F).